Bioluminescence Ventures — Full Portfolio
5 tracked investments · listed companies and verified rows first
Palo Alto, US
Board seatKouki Harasaki· per SEC Form D · $22.2M raise · filed May 2021
Ensoma is a genomic medicine company developing a platform for in vivo engineering of hematopoietic stem cells (HSCs), combining an off-the-shelf delivery system with a gene engineering toolkit intended to treat diseases with a one-time treatment.
BiotechHealthtechMedical DevicesBoston, US
Board seatKouki Harasaki· per SEC Form D
Co-investors5AM VenturesAju IB Invesment CorporationCatalio Capital Management, LPDelos CapitalF-Prime CapitalSolasta Ventures+7 more
Karlsgate provides a data governance and identity protection platform (the Karlsgate Identity Exchange) that lets organizations match, share, and collaborate on sensitive data across partners and AI workflows without transmitting raw identifiers, using locally generated cryptonyms and single-use protected values.
CybersecurityData & InfrastructureEnterprise SoftwareBudd Lake, US
Brian Mulllin(Executive Officer, Director)Xian Zhou(Executive Officer, Director)Kouki Harasaki(Director)
Board seatKouki Harasaki· per SEC Form D · $5M raise · filed Mar 2022
Co-investorsMotley Fool Ventures
ReCode develops mRNA and gene correction therapeutics for genetic diseases, using proprietary lipid nanoparticle technology to deliver treatments to specific organs.
AI & Machine LearningBiotechHealthtechMedical DevicesMenlo Park, US
Dr. Daniel J. SiegwartArthur E Johnson(Executive Officer, Director)
Board seatKouki Harasaki· per SEC Form D · $290M raise · filed Sep 2023
Co-investorsAju IB Invesment CorporationEcoR1 CapitalEvolution VC PartnersMPM BioImpactOrbiMedOUP (Osage University Partners)+6 more
Cambridge, US
Board seatKouki Harasaki· per SEC Form D · $50M raise · filed Jun 2023
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.